The main purpose of this study was to evaluate the therapeutic effect of hADSCs modified with VEGFA modRNA and bFGF modRNA (hADSCsVEGFA, hADSCsbFGF and hADSCsdual) in promoting angiogenesis, inhibiting apoptosis, improving cardiac function, and inducing beneficial outcomes following MI. The gene discussed is FGF2; the disease is myocardial infarction.